You searched for "ESCRS"
PRN Ranibizumab verses continuous aflibercept in UK clinical practice
This was a multicentre (21 UK hospitals), national EMR study on treatment naïve nAMD eyes, undergoing predominantly as needed (PRN) Ranibizumab or continuous (fixed or treat and extend - (F/TE)) Aflibercept (Af). The primary outcome was change in vision at...
Anatomical and functional outcomes following switching from aflibercept to ranibizumab in NARMD
This is a six-month, prospective, single-arm study in the UK and Germany. A total of 100 patients were enrolled (one in the primary failure group, 99 in the suboptimal treatment response group), treated three-monthly intravitreal ranibizumab injections (0.5mg), and then...The Scottish Optometry Awards
Join us at the inaugural Scottish Optometry Awards dinner dance at the Glasgow Radisson Blu Hotel on Saturday 15th November. Drinks 7.00 for 7.30pm. Dinner 7.30–9.00pm. Awards 9.00–9.30pm. Dancing with DJ 9.30–11.30. On the Saturday evening at the Scottish Optical...
Insights in resistant diabetic macular oedema
This article gives a bird’s eye review of the different modalities for the treatment of diabetic macular oedema (DME). The debut of anti-VEGFs has brought a paradigm shift in DME management. This treatment has now become a major breakthrough in...Dr Glaucomflecken: Stayin’ Alive
Peter Cackett spoke to ophthalmologist and social media sensation Dr Glaucomflecken about his early days in comedy, the role satire can play in impacting medical governance, and where he might take his brand of medical comedy next. It was towards...Coming to terms with AI
A machine might be called intelligent if its response to questions could convince a person that it was human, a test proposed by Alan Turing in 1950 [1]. The author considers potential applications of artificial intelligence (AI) using machine learning...See sweet to C-suite: Imran Rahman
See also - See sweet to C-suite: Peter Holland In this three-part conversation series, Co-editor David Lockington speaks with highly influential individuals about their journey to the top, with advice for the next generation of leaders. Part Two: David speaks...
Post hoc analysis of the CANTREAT randomised trial
CANTREAT, a Canadian multicentre two-year randomised trial compares treat and extend treatment (T&E) relative to the monthly administration of Ranibizumab in nAMD. Two-hundred and eighty-five treatment-naïve patients with nAMD were randomised to receive either a once-monthly dosing or T&E regimen...
Long-term outcomes of intravitreal ranibizumab for neovascular AMD
This is a single centre prospective study for the long-term, whole population ‘real-world’ clinical outcomes of ranibizumab therapy in treatment-naïve patients for neovascular age-related macular degeneration (AMD). This study recorded: demographics, Early Treatment Diabetic Retinopathy Study visual acuity (ETDRS VA)...
Results of fixed aflibercept treatment regime in type 3 neovascularisation
In this prospective study the authors evaluate the effect of intravitreal aflibercept injections in the treatment of naive type 3 neovascularisation using a fixed treatment regime. Fourteen eyes of 14 patients were studied. All patients were treated with intravitreal 2.0...
Verteporfin shortage: treatment options and outcomes in chronic non-resolving central serous chorioretinopathy
Half-dose photodynamic therapy (HD-PDT) with verteporfin has been the therapy of choice in non-resolving central serous chorioretinopathy lasting longer than four months. Since 2021, a worldwide shortage of verteporfin due to manufacturing issues prompted adjustments in treatment practices. This retrospective,...
